Periodontal Follow-up and Glycemy in Patients With Type 2 Diabetes

NCT ID: NCT07165171

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 516 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2030-10-01

Brief Summary

Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.

Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.

Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.

Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.

The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.

Detailed Description

Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.

Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.

Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.

Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.

However, periodontitis is a recurring disease; The implementation of periodontal monitoring (SuP) is essential throughout life after periodontal treatment, in order to prevent relapses. This monitoring, which must be carried out for life, includes the reassessment of periodontal criteria, professional instrumentation and oral hygiene (HBD) advice.

Visits every 3 months are generally recommended at the beginning, in order to regularly reinforce HBD advice. However, adherence to the SuP is difficult to obtain in the long term. In orthodontic patients, the use of reminder systems (SMS, emails, mobile applications, etc.) has a positive effect on HBD and periodontal criteria and would improve the rate of attendance at appointments in the medium term (3-12 months). A reminder and reinforcement system for HBD advice could therefore be integrated into the SuP in order to improve HBD and longer-term adherence in diabetic patients.

The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.

This is a comparative experimental study to evaluate the effectiveness of a new monitoring strategy for type 2 diabetic patients who have been treated for periodontitis, a randomized controlled trial including an implementation study using a mixed methods approach (quantitative and qualitative).

The research will take place in 7 hospitals (Lille, Lyon, Nantes, Paris, Rennes, Strasbourg, Toulouse) and 7 privates dental centers in France.

Two types of care are proposed after periodontal treatment (all patients included will have previously benefited from standard periodontal treatment in the different centers).

The two groups compared will be:

• For the Experimental Group: Innovative periodontal monitoring.
• For the Control Group: Standard periodontal follow-up.

The primary endpoint is the HbA1c level (expressed in %) at 2 years after the date of randomization. The HbA1c level at 2 years will be collected by performing a routine dosage, in the patient's usual laboratory.

The target population of the GlyCoSuP project concerns adults with type 2 diabetes who have been treated for periodontitis.

After increasing by 10% to take into account those lost to follow-up, the total number of patients to be included will be 516 (258 patients per arm).

The duration of the inclusion period will be 24 months and the participation for each subject will be 24 months. In total, the total duration of the study will be 48 months.

Conditions

Periodontal Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Intervention group: SuP innovant (sending Short Message Service - SMS)

For the Experimental Group: Innovative periodontal monitoring (SuP), consisting of:

• visits every 3 months during 24 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary. (common to the control group)
• sending of different types of SMS: different types of SMS messages will be sent alternately.

The SMS messages are intended for patients in the experimental group. The proposed approach aims to maintain contact with the patient at home and strengthen their commitment to a good oral hygiene routine over the long term. Text messages will be sent via the French CURECALL platform.

The various text messages will be scheduled from the beginning of the periodontal follow-up.

Group Type: EXPERIMENTAL

Innovative periodontal monitoring (SuP innovative)

Intervention Type: PROCEDURE

Different types of SMS messages will be sent alternately.

• Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients.
• Type 2 SMS: Interactive SMS text messages written in the form of questions.
• Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment.

The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient:

• 1 Type 1 SMS/week (medical advice or information);
• 1 Type 2 SMS/month (interactive with suggested answers);
• 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up.

Control group: SuP standard

For the Control Group: Standard periodontal follow-up (SuP), consisting of: visits every 3 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary (common to the experimental group).

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Innovative periodontal monitoring (SuP innovative)

Different types of SMS messages will be sent alternately.

• Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients.
• Type 2 SMS: Interactive SMS text messages written in the form of questions.
• Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment.

The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient:

• 1 Type 1 SMS/week (medical advice or information);
• 1 Type 2 SMS/month (interactive with suggested answers);
• 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up.

Intervention Type: PROCEDURE

Other Intervention Names

Innovative periodontal monitoring (SuP innovative

Eligibility Criteria

Inclusion Criteria

• -- Adult aged 18 years or older;
• Presenting with type 2 diabetes (under ALD), balanced or not, for 6 months or more;
• Having been treated in the previous 6 months for periodontitis (stages 1 to 4 according to the new classification of periodontal and peri-implant diseases EFP-AAP 2018) in one of the participating centers and presenting a clinical situation allowing the transition to the periodontal follow-up phase (; (absence or limited number of sites presenting clinical signs of persistent periodontal inflammation)
• Presenting more than 6 teeth;
• Possessing a smartphone or tablet with internet access;
• Affiliated to social security;
• Patient able to read, write and understand French
• Having signed a consent to participate in the study.

Exclusion Criteria

• Patient presenting uncontrolled systemic diseases and diagnosed for less than 6 months or presenting a major aggravation of a systemic pathology according to the judgment of the investigator.
• Pregnant or breastfeeding women;
• Persons deprived of liberty by a judicial or administrative decision;
• Adults subject to a legal protection measure (guardianship, curatorship).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hôpital Charles Foix

Ivry-sur-Seine, , France

Centre Hospitalo-Universitaire de Lille

Lille, , France

Hospices Civils de Lyon, Centre de Soins Dentaires.

Lyon, , France

Centre Hospitalo-Universitaire de Nantes

Nantes, , France

Centre Hospitalo-Universitaire de Rennes

Rennes, , France

Cabinet libéral

Saint-Victor-de-Cessieu, , France

Hôpitaux universitaires de Strasbourg

Strasbourg, , France

Centre Hospitalo-Universitaire de Toulouse

Toulouse, , France

Countries

France

Central Contacts

Kerstin GRITSCH, Prefessor

Role: CONTACT

kerstin.gritsch@chu-lyon.fr

4 27 85 40 30 ext. +33

Julie HAESEBAERT, Professor

Role: CONTACT

julie.haesebaert01@chu-lyon.fr

472115165 ext. +33

Facility Contacts

Marjolaine GOSSET, Pr

Role: primary

marjolaine.gosset@aphp.fr

1 49 59 48 03 ext. +33

Kevimy AGOSSA, Pr

Role: primary

kevimy.agossa@univ-lille.fr

3 20 44 43 55 ext. +33

Brigitte GROSGOGEAT, Professor

Role: primary

brigitte.grosgogeat@chu-lyon.fr

0662162525 ext. +33

Xavier STRUILLOU, MD

Role: primary

6 61 37 46 16 ext. +33

Helene Rangé, Pr

Role: primary

helene.range@chu-rennes.fr

02 99 28 24 00

Marie BARRAS, MD

Role: primary

drbarras.marie@gmail.com

4 74 90 35 19 ext. +33

Olivier HUCK, Pr

Role: primary

o.huck@unistra.fr

3 88 11 69 47 ext. +33

Sara LAURENCIN, DM

Role: primary

sara.laurencin-dalicieux@univ-tlse3.fr

6 80 43 87 15 ext. +33

Other Identifiers

2024-A01407-40

Identifier Type: OTHER

Identifier Source: secondary_id

69HCL23_0377

Identifier Type: -

Identifier Source: org_study_id